Monday, January 2, 2012

Healthcare Business Brief: Humana Spotlighted for 2012, Amgen Catches an Upgrade

Stryker (NYSE:SYK) is accused by Synthes in a lawsuit of raiding its San Francisco sales force and using confidential information from former employees. Synthes says in a complaint filed today that Stryker seeks to obtain “an improper competitive advantage�� in the industry for medical implants and instruments used in spinal surgery.

Investing Insights: Are Shareholders Benefiting From the Health Conscious Consumer?

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares jump after the developer of antibodies to treat cancer and viral infections says results for its bavituximab drug preliminary phase II trial to treat patients with hepatitis C showed antiviral activity. And, the treatment is safe.

Humana (NYSE:HUM) is seen by Investment U as one the best defensive stocks for 2012. Investment U notes that the impacts of new healthcare rules are minimal and the firm has substantial growth potential. A large number of analysts, roughly 68% of them rate the stock a Buy and the rest no worse than a Hold.

Bank of America (NYSE:BAC) weighs in on Amgen (NASDAQ:AMGN) after digesting recent events related to the firm including its planned buyback of $5 billion worth of stock. Analysts cite prescription sales trends and a favorable dollar to euro climate as drivers, as they slot in 2012 earnings per share at $6.13 vs. Wall Street��s $5.82.

To contact the reporter on this story: Tanya Harding at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com

Related Articles:

The MicroPlace Ambition - Unleashing $35 Billion in Financial Services Funding to the World's Working Poor

Is II-VI's Growth for R! eal?

Tags: GIIN ,Hot China Stocks ,Hot Stocks To Buy For 2012 ,Hot Stocks To Invest In ,Hot Stocks To Invest In 2012 ,Best China Stocks 2012

No comments:

Post a Comment